Yu Jian, Yue Wen, Wu Bin, Zhang Lin
Department of Pathology, University of Pittsburgh School of Medicine, Hillamn Cancer Center, Pittsburgh, Pennsylvania 15213, USA.
Clin Cancer Res. 2006 May 1;12(9):2928-36. doi: 10.1158/1078-0432.CCR-05-2429.
Lung cancer, the leading cause of cancer mortality worldwide, is often diagnosed at late stages and responds poorly to conventional therapies, including chemotherapy and irradiation. A great majority of lung tumors are defective in the p53 pathway, which plays an important role in regulating apoptotic response to anticancer agents. PUMA was recently identified as an essential mediator of DNA damage-induced and p53-dependent apoptosis. In this study, we investigated whether the regulation of PUMA by anticancer agents is abrogated in lung cancer cells and whether PUMA expression suppresses growth of lung cancer cells and/or sensitizes lung cancer cells to chemotherapeutic agents and irradiation through induction of apoptosis.
The expression of PUMA was examined in lung cancer cells with different p53 status treated with chemotherapeutic agents. An adenovirus expressing PUMA (Ad-PUMA), alone or in combination with chemotherapeutic agents or gamma-irradiation, was used to treat lung cancer cells. The growth inhibitory and apoptotic effects of PUMA in vitro and in vivo were examined. The mechanisms of PUMA-mediated growth suppression and apoptosis were investigated through analysis of caspase activation and release of mitochondrial apoptogenic proteins. The cytotoxicities of PUMA on cancer and normal/nontransformed cells were compared. The efficacy of PUMA and p53 in suppressing the growth of lung cancer cells was also compared.
We showed that the induction of PUMA by chemotherapeutic agents is abolished in p53-deficient lung cancer cells. PUMA expression resulted in potent growth suppression of lung cancer cells and suppressed xenograft tumor growth in vivo through induction of apoptosis. Low dose of Ad-PUMA significantly sensitized lung cancer cells to chemotherapeutic agents and gamma-irradiation through induction of apoptosis. The effects of PUMA are mediated by enhanced caspase activation and release of cytochrome c and apoptosis-inducing factor into the cytosol. Furthermore, PUMA seems to be selectively toxic to cancer cells and more efficient than p53 in suppressing lung cancer cell growth.
Our findings indicate that PUMA is an important modulator of therapeutic responses of lung cancer cells and is potentially useful as a sensitizer in lung cancer therapy.
肺癌是全球癌症死亡的主要原因,通常在晚期被诊断出来,对包括化疗和放疗在内的传统疗法反应不佳。绝大多数肺肿瘤在p53通路中存在缺陷,该通路在调节对抗癌药物的凋亡反应中起重要作用。PUMA最近被确定为DNA损伤诱导的和p53依赖性凋亡的关键介质。在本研究中,我们调查了抗癌药物对PUMA的调节在肺癌细胞中是否被废除,以及PUMA表达是否通过诱导凋亡抑制肺癌细胞的生长和/或使肺癌细胞对化疗药物和放疗敏感。
在用化疗药物处理的具有不同p53状态的肺癌细胞中检测PUMA的表达。使用表达PUMA的腺病毒(Ad-PUMA)单独或与化疗药物或γ射线联合用于治疗肺癌细胞。检测了PUMA在体外和体内的生长抑制和凋亡作用。通过分析半胱天冬酶激活和线粒体凋亡蛋白的释放来研究PUMA介导生长抑制和凋亡的机制。比较了PUMA对癌细胞和正常/未转化细胞的细胞毒性。还比较了PUMA和p53在抑制肺癌细胞生长方面的功效。
我们表明,化疗药物对PUMA的诱导在p53缺陷的肺癌细胞中被消除。PUMA表达导致肺癌细胞的有效生长抑制,并通过诱导凋亡抑制体内异种移植肿瘤的生长。低剂量的Ad-PUMA通过诱导凋亡使肺癌细胞对化疗药物和γ射线显著敏感。PUMA的作用是通过增强半胱天冬酶激活以及细胞色素c和凋亡诱导因子释放到细胞质中来介导 的。此外,PUMA似乎对癌细胞具有选择性毒性,并且在抑制肺癌细胞生长方面比p53更有效。
我们的研究结果表明,PUMA是肺癌细胞治疗反应的重要调节因子,并且有可能作为肺癌治疗中的增敏剂。